Journal of Antimicrobial Chemotherapy, Vol 41, 373-380, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy
V Krcmery Jr, E Oravcova, S Spanik, M Mrazova-Studena, J Trupl, A Kunova, K Stopkova-Grey, E Kukuckova, I Krupova, A Demitrovicova and K Kralovicova
Forty-one episodes of breakthrough fungaemia occurring over a 7.5 year
period in the National and St Elizabeth's Cancer Institutes in Bratislava,
Slovakia, were analysed. Five of them occurred during prophylaxis with
fluconazole (one Torulopsis glabrata, one Hansenula anomala, two Candida
krusei and one Candida parapsilosis), ten with itraconazole (three
Trichosporon pullulans, one Trichosporon beigelii, one Cryptococcus
laurentii, three Candida albicans and two T. glabrata), 11 during
prophylaxis with ketoconazole (one Candida norvegenesis, one C.
parapsilosis, one C. krusei, one Candida tropicalis, five C. albicans, one
Candida stellatoidea and one C. laurentii and 15 during empirical therapy
with amphotericin B (ten C. albicans, two T. beigelii and three Candida
lusitaniae). The most frequent risk factors for breakthrough fungaemia were
neutropenia, previous therapy with multiple antibiotics and recent catheter
insertion. Comparing these episodes with 38 non-breakthrough fungaemias
(appearing at the same institute in the same period) differences in certain
risk factors were noted: breakthrough fungaemias were more frequently
observed in patients with acute leukaemia (39.0% vs 5.2%, P < 0.001),
mucositis (34.2% vs 13.1%, P < 0.05), prophylaxis with quinolones (58.5%
vs 15.8%, P < 0.0001) and catheter-associated infections (29.3% vs 2.6%,
P < 0.003). In this subgroup overall mortality (36.6% vs 28.8%) or early
attributable mortality (22.0% vs 23.6%) were not significantly different.
ORIGINAL ARTICLES
Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology risk factors and outcome
Department of Medicine, University of Trnava, Slovakia.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. L. R. da Matta, M. d. S. C. Melhem, A. L. Colombo, M. L. Moretti, L. Rodero, G. M. D. de Almeida, M. d. A. Martins, S. F. Costa, M. B. G. Souza Dias, M. Nucci, et al. Antifungal Drug Susceptibility Profile of Pichia anomala Isolates from Patients Presenting with Nosocomial Fungemia Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1573 - 1576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Li, S. Redding, and A. Dongari-Bagtzoglou Candida glabrata, an Emerging Oral Opportunistic Pathogen Journal of Dental Research, March 1, 2007; 86(3): 204 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Spellberg, M. Collins, V. Avanesian, M. Gomez, J. E. Edwards Jr., C. Cogle, D. Applebaum, Y. Fu, and A. S. Ibrahim Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts J. Leukoc. Biol., March 1, 2007; 81(3): 632 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. P. Chong, D. C.-S. Chieng, L. Y. Low, A. Hafeez, M. N. Shamsudin, H. F. Seow, and K. P. Ng Recurrent candidaemia in a neonate with Hirschsprung's disease: fluconazole resistance and genetic relatedness of eight Candida tropicalis isolates. J. Med. Microbiol., April 1, 2006; 55(Pt 4): 423 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Spellberg, M. Collins, S. W. French, J. E. Edwards Jr, Y. Fu, and A. S. Ibrahim A phagocytic cell line markedly improves survival of infected neutropenic mice J. Leukoc. Biol., August 1, 2005; 78(2): 338 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Munoz, M. Sanchez-Somolinos, L. Alcala, M. Rodriguez-Creixems, T. Pelaez, and E. Bouza Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital J. Antimicrob. Chemother., February 1, 2005; 55(2): 188 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Pfaller, S. A. Messer, L. Boyken, S. Tendolkar, R. J. Hollis, and D. J. Diekema Geographic Variation in the Susceptibilities of Invasive Isolates of Candida glabrata to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002 J. Clin. Microbiol., July 1, 2004; 42(7): 3142 - 3146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.A. EL-MAHALLAWY, I. ATTIA, N.H. ALI-EL-DIN, A.E. SALEM, and S. ABO-EL-NAGA A prospective study on fungal infection in children with cancer J. Med. Microbiol., July 1, 2002; 51(7): 601 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. KRCMERY, L. LAHO, M. HUTTOVA, A. ONDRUSOVA, K. KRALINSKY, L. PEVALOVA, S. DLUHOLUCKY, M. PISARCuIKOVA, J. HANZEN, J. FILKA, et al. Aetiology, antifungal susceptibility, risk factors and outcome in 201 fungaemic children: data from a 12-year prospective national study from Slovakia J. Med. Microbiol., February 1, 2002; 51(2): 110 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Krcmery, M. Huttova, F. Mateicka, L. Laho, L. Jurga, A. Ondrusova, Z. Tarekova, K. Kralinsky, J. Hanzen, A. Liskova, et al. Breakthrough fungaemia in neonates and infants caused by Candida albicans and Candida parapsilosis susceptible to fluconazole in vitro J. Antimicrob. Chemother., October 1, 2001; 48(4): 521 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Khan and J. R. Wingard Infection and Mucosal Injury in Cancer Treatment J Natl Cancer Inst Monographs, October 1, 2001; 2001(29): 31 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Cardenas, M. C. Cruz, M. Del Poeta, N. Chung, J. R. Perfect, and J. Heitman Antifungal Activities of Antineoplastic Agents: Saccharomyces cerevisiae as a Model System To Study Drug Action Clin. Microbiol. Rev., October 1, 1999; 12(4): 583 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Girishkumar, A. M Yousuf, J. Chivate, and E. Geisler Experience with invasive Candida infections Postgrad. Med. J., March 1, 1999; 75(881): 151 - 153. [Abstract] [Full Text]
|
|